Opendata, web and dolomites

TIR-C SIGNED

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TIR-C project word cloud

Explore the words cloud of the TIR-C project. It provides you a very rough idea of what is the project "TIR-C" about.

cream    vital    unresolved    relives    damage    operate    moderate    survey    defences    persons    safe    dermatology    regulatory    dermatitis    kols    therapy    expenditures    escalation    societies    itch    unmet    lesions    intravenously    mild    deprivation    works    interfere    economic    steroid    sufferers    infected    symptoms    rate    productivity    commercialisation    blockbuster    life    market    validate    self    topical    profile    clinicians    anti    poses    confirm    diabetes    tir    conduct    extremely    water    consequently    communicated    unsuitable    treatment    children    preparations    prevent    iia    local    inflammation    approvals    80    sleep    psychological    trials    contain    disease    pharma    skin    cro    symptom    contract    atopic    manufacturing    pricing    immune    biologics    action    tirmed    plan    excellent    formulation    affordable    freedom    mind    burden    severe    feasibility    patient    health    entirely    eliminate    safety    ab    drafted    group    administrated    costly    readiness    enormous    consistently    quality    patients    steroids    clinical    mechanism    ad   

Project "TIR-C" data sheet

The following table provides information about the project.

Coordinator
TIRMED PHARMA AB 

Organization address
address: SPETS ALVIKSVAGEN 1
city: BROMMA
postcode: 16753
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIRMED PHARMA AB SE (BROMMA) coordinator 50˙000.00

Map

 Project objective

TIRmed pharma AB has developed a non-steroid cream that relives itch in Atopic Dermatitis (AD). Itch is an enormous, unresolved symptom in AD, induced by inflammation and skin damage. AD poses a significant burden on societies and patients’ quality of life due to itch, infected lesions, sleep deprivation, and consequently productivity loss, psychological health and treatment-associated expenditures. Persons affected by AD consistently rate AD management to be comparable to diabetes management. Our TIR-C cream doesn’t contain steroids and works through an entirely novel mechanism of action. The therapy has been developed with the largest patient group in mind; children. TIR-C has the potential to become a blockbuster in AD management as it has an excellent safety profile, is very affordable, is easy to self-apply (water-based), doesn’t interfere with vital immune defences and has the potential to prevent disease escalation. We target mild-to-moderate symptoms (80% of all AD sufferers), aiming to eliminate the need for intravenously administrated biologics. Biologics are not only extremely costly, but also associated with severe side effects, making them unsuitable for children. The unmet need for safe, topical anti-itch-treatment in persons with mild-to-moderate AD has been clearly communicated by leading contract research organizations, KOLs and clinicians within dermatology. TIR-C is at Technology Readiness Level 4 with established manufacturing and formulation processes and a clinical development plan drafted in collaboration with a leading CRO in dermatology. The proposed feasibility study will advance preparations for commercialisation by allowing us to confirm regulatory requirements needed for market approvals, validate pricing through a health-economic survey in the EU, identify a local CRO to conduct the planned phase I/IIa clinical trials and confirm Freedom to Operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIR-C" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIR-C" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More